Blogs
Turquoise Is Now A CMS Qualified Entity
Which means CMS certified us to work with Medicare claims data

Turquoise has just been certified as a Qualified Entity (QE) under the Centers for Medicare & Medicaid Services' Qualified Entity Certification Program.
It's not every day the federal government certifies we know how to handle America's most sensitive healthcare data. For those who don’t know, that means CMS reviewed how we ingest, secure, manage, and report on protected health information and claims data, and decided we're trustworthy enough to work with Medicare's data. Earned only by proving your data pipeline unimpeachable and your data practices of the highest order, the QE designation is an honor, and we're even more excited to dig into the new data now available to us as a QE.
Medicare claims data under Parts A, B, and D is heading to Turquoise soon
As a QE, in the coming months, we'll be able to access and report on Medicare claims data under Parts A, B, and D.
That means we’ll soon have:
- Actual utilization and payment data
- Care settings price transparency data doesn’t currently touch (like skilled nursing facilities, home health, hospice, DME, and physician office claims)
- Part D prescription drug event data (pharmacy benefit, fill-level detail)
- Diagnoses and clinical context
- Longitudinal patient journeys
- Payment adjudication detail
How is this different from the commercial claims data we already coupled with price transparency data? Well, commercial claims data is licensed from an aggregator, originally submitted by entities that choose to share it. That data is good but not reliably robust (hence why it acts as a great accompaniment to price transparency data!). Since almost every provider in the country submits claims to Medicare, Medicare data doesn’t suffer from the same gaps as commercial claims. Even a sample of Medicare data is universal in a way commercial claims isn't—there's no market segment Medicare misses, because there's no provider it doesn't touch. Alongside the commercial payer focus of MRF payer rates, this data set is focused on a different population (since Medicare data skews older and sometimes sicker than a commercially insured population) and a different level of granularity.
Basically, as a QE, we can now work directly with charge, payment, and utilization data alongside negotiated rate data. In addition to this new data, as a QE, we’re now required to report on CMS-approved provider performance measures. More on that soon!
It’s not just more data, it’s another piece of the complexity puzzle
This new data sharpens the resolution of Clear Rates—the foundational model of the rates, rules, and relationships underlying how U.S. healthcare gets paid and the foundation of the Turquoise platform. That directly strengthens our ability to simplify the financial complexity of healthcare. Once the data is in hand, we’ll be able to continue to evolve the PATIENT Framework’s Standard Service Packages (SSPs), our open-source, patient-first grouping methodology that collapses the revenue cycle to a single encounter-level price, reducing administrative overhead and enabling guaranteed upfront costs for patients.
Take a knee replacement, for example. Does that SSP look identical for a commercially insured patient and a Medicare patient, or does it diverge in ways the aggregated data can't show? Right now that's a real question we’re unable to answer. With claims-level Medicare data, it's one we can actually go answer and use to confirm existing SSPs or build new ones specific to that population.
More to come soon
Once the claims data starts flowing, it's a field day for us healthcare data enthusiasts. Look out for future reporting on the scintillating insights we find.

How to avoid fast-fashioned price transparency reports
It wouldn't be a Turquoise blog without an extended metaphor.

String cleaning payer name and class models in price transparency data
We’ll let you be the judge on whether or not this should be referred to as “Data Flossing.”

A new level of accountability is here for hospitals
When CMS publishes a long document, you best believe we’ll stay up all night reading it.

Live from the tech stack
Our product and engineering teams share initial reactions to the Proposed Rule.

Episodes of care: JAWS
In celebration of Shark Week, we thought we'd remind the internet that fish are friends, not food.

Drug prices are about to be under the CMS looking glass
2024 Proposed Rule increases what drug reporting hospitals must include within their MRFs.

Price transparency will be transformed by the 2024 proposed rule
A review of the evolution of hospital price transparency.
No results found
There are no results with this criteria. Try changing your search.
